Is lobular carcinoma in situ considered cancer?
Lobular carcinoma in situ (LCIS), also known as lobular neoplasia, is a rare condition in which abnormal cells develop in the milk glands, known as lobules, in the breast. These abnormal cells are not considered to be breast cancer and don’t require any treatment beyond surgical removal.
Is DCIS malignant or benign?
If these abnormal cells, which are uncontrollably growing, stay inside the duct, they are referred to as Ductal Carcinoma In-Situ (DCIS). They are ductal cells that have become malignant, but they have remained in their original place (in-situ) and are thus a noninvasive cancer.
Is in situ breast cancer malignant?
Ductal carcinoma in situ (DCIS) means the cells that line the milk ducts of the breast have become cancer, but they have not spread into surrounding breast tissue. DCIS is considered non-invasive or pre-invasive breast cancer.
Is LCIS a premalignant?
Initially LCIS was considered a premalignant lesion, but it is now a marker of increased risk. The number of women diagnosed with LCIS has increased in recent years most likely owing to more rigorous breast cancer screening.
What stage is lobular carcinoma in situ?
Stage 0 means the cancer cells are still within the breast lobule and have not invaded deeper into the surrounding fatty breast tissue. This is called lobular carcinoma in situ (LCIS), a non-invasive breast cancer. In stage 0 cancer, the cancer has not spread to lymph nodes or distant sites.
Should I have a mastectomy for LCIS?
Unlike breast cancer, LCIS does not form a tumor. Unlike DCIS, it does not form abnormal cells that can develop into invasive cancer. That is why no surgery is needed to remove LCIS.
Can DCIS spread after biopsy?
Because DCIS is not an invasive cancer and cannot spread to other parts of the body, whole body treatments, like chemotherapy, are not indicated for this stage of disease.
What is the treatment for carcinoma in situ?
TREATMENT APPROACH Patients with DCIS undergo local treatment with breast-conserving therapy (BCT) or mastectomy. BCT consists of lumpectomy (also called breast-conserving surgery, wide excision, or partial mastectomy) followed in most cases by adjuvant radiation.
Which is worse LCIS or DCIS?
This is in contrast to LCIS which has risk for the development of invasive breast cancer in either breast over time. In summary, LCIS is considered a risk factor for invasive cancer while DCIS is considered a precursor to invasive cancer.
What’s the most aggressive breast cancer?
Triple-negative breast cancer (TNBC) is considered an aggressive cancer because it grows quickly, is more likely to have spread at the time it’s found and is more likely to come back after treatment than other types of breast cancer. The outlook is generally not as good as it is for other types of breast cancer.
Does LCIS need to be treated?
LCIS does not require treatment in the way you might normally think of cancer treatment, such as needing to have surgery, radiation therapy, and chemotherapy. You and your doctor may decide that you should undergo careful observation to watch for any signs of invasive breast cancer.
Does LCIS spread?
LCIS is not considered to be cancer, and it typically does not spread beyond the lobule (become invasive breast cancer) if it isn’t treated. But having LCIS does increase your risk of developing an invasive breast cancer in either breast later on, so close follow-up is important.
How fast does LCIS progress?
Another estimate suggests that an LCIS diagnosis increases breast cancer risk to 21% over the next 15 years. If a woman with LCIS develops an invasive breast cancer, it doesn’t typically happen within a few years. Rather, it is more likely to happen over the long-term — in 10, 15, or 20 years or even beyond that.